Su Benli, Liu Haixia, Li Jing, Sunli Yongjuan, Liu Ben, Liu Dandan, Zhang Ping, Meng Xiuxiang
Department of Endocrinology and Metabolism, The Second Affiliated Hospital of Dalian Medical University, Dalian, China.
Laboratory Center for Clinical Diagnosis, Dalian Medical University, Dalian, China.
J Diabetes. 2015 Sep;7(5):729-39. doi: 10.1111/1753-0407.12232. Epub 2015 Jan 15.
The effects of acarbose add-on therapy on gut microbiota and inflammatory cytokines were investigated in Chinese patients with type 2 diabetes mellitus (DM).
Ninety-five DM patients were randomly allocated to two groups: 59 to Group A who received antidiabetic treatment that included acarbose 150 mg/day, and 36 to Group B who received similar treatment to Group A but without acarbose. Forty-five healthy volunteers were selected as a control group. Serum concentrations of inflammatory cytokines were determined by ELISA, and the contents of 16S rDNA of gut bacteria were determined by real-time quantitative polymerase chain reaction. General linear analysis for repeated measurements was used to analyze trend differences between the two diabetic groups.
After 4 weeks of antidiabetic treatment, the gut contents of Bifidobacterium longum and Enterococcus faecalis were significantly increased in both diabetes groups. The increase of Bifidobacterium longum (P = 0.004) and the decrease of lipopolysaccharides (LPS) (P < 0.001) and prothrombin activator inhibitor-1 (P = 0.003) were more significant in Group A. Decreases of monocyte chemoattractant protein-1 and LPS were more significant in patients whose HbA1c decrease was ≥1%, but there were no significant differences in the changes of other cytokines and gut bacteria between patients with HbA1c <7% and ≥7%. Pearson correlation analysis showed that changes of Enterococcus faecalis were negatively correlated with LPS, while multiple linear regression analysis showed a positive correlation of Bifidobacterium longum with acarbose treatment and the high-density lipoprotein cholesterol concentration.
Acarbose treatment can increase the content of gut Bifidobacterium longum in type 2 diabetes mellitus patients and decrease some inflammatory cytokines independently of its antihyperglycemic effects.
在中国2型糖尿病（DM）患者中，研究了阿卡波糖附加疗法对肠道微生物群和炎性细胞因子的影响。
95例DM患者被随机分为两组：59例进入A组，接受包括每日150mg阿卡波糖的抗糖尿病治疗；36例进入B组，接受与A组相似但不含阿卡波糖的治疗。选取45名健康志愿者作为对照组。采用酶联免疫吸附测定法测定血清炎性细胞因子浓度，采用实时定量聚合酶链反应测定肠道细菌16S rDNA的含量。采用重复测量的一般线性分析来分析两个糖尿病组之间的趋势差异。
抗糖尿病治疗4周后，两个糖尿病组中长双歧杆菌和粪肠球菌的肠道含量均显著增加。A组中长双歧杆菌的增加（P = 0.004）以及脂多糖（LPS）的减少（P < 0.001）和凝血酶原激活物抑制剂-1的减少（P = 0.003）更为显著。糖化血红蛋白（HbA1c）下降≥1%的患者中单核细胞趋化蛋白-1和LPS的下降更为显著，但HbA1c < 7%和≥7%的患者之间其他细胞因子和肠道细菌的变化无显著差异。Pearson相关性分析显示粪肠球菌的变化与LPS呈负相关，而多元线性回归分析显示长双歧杆菌与阿卡波糖治疗和高密度脂蛋白胆固醇浓度呈正相关。
阿卡波糖治疗可增加2型糖尿病患者肠道中长双歧杆菌的含量，并独立于其降血糖作用降低一些炎性细胞因子。
